drugset / Trial / NCT04094766
Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia
Phase 1
Withdrawn
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of dual specificity CD19 and CD22 CAR-T cells in patients with relapsed and refractory acute B lymphoblastic leukemia.
Timeline
- Start
- 2017-08-01
- Primary completion
- 2020-08-30
- Completion
- 2020-08-30
Outcome
Outcome not reported
Stopped: “Production plan adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy | Cell therapy | 1.5e+06 cells/kg | Intravenous |
| Subject | Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy | Cell therapy | 2e+06 cells/kg | Intravenous |